Panobinostat, a pan-histone deacetylase inhibitor: Rationale for and application to treatment of multiple myeloma
The DOI matches its Crossref record.
Abstract
Histone deacetylase inhibitors (HDACis) have emerged as novel therapeutic agents for cancer. Currently, four HDACis are approved by the Food and Drug Administration (FDA) to treat various hematologic malignancies. Panobinostat (LBH-589, trade name Farydak®, developed and marketed by Novartis) is a potent pan-HDACi with demonstrated anticancer activities against multiple myeloma, a B-cell malignancy, at a low nanomolar range in preclinical settings, and in 2015 was granted FDA approval for the treatment of relapsed and refractory multiple myeloma. Here, we review the development of HDACis, the unique features of panobinostat, and the rationale for developing panobinostat in a combination setting for the treatment of multiple myeloma. We also review the completed and ongoing clinical trials testing the efficacy of panobinostat in combination therapies and highlight future therapeutically relevant strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Toward Multi-Targeted Platinum and Ruthenium Drugs—A New Paradigm in Cancer Drug Treatment Regimens?
Kenny, R. G., & Marmion, C. J. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00271 · Cited by 636
Cancer Cell Metabolism in Hypoxia: Role of HIF-1 as Key Regulator and Therapeutic Target
Infantino, V., Santarsiero, A., Convertini, P., Todisco, S., & Iacobazzi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115703 · Cited by 499
Lagoumtzi, S. M., & Chondrogianni, N. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.05.003 · Cited by 279
He, F., Chou, C. J., Scheiner, M., Poeta, E., Yuan Chen, N., Gunesch, S., Hoffmann, M., Sotriffer, C., Monti, B., Maurice, T., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01940 · Cited by 66
Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition
Hendrick, E., Peixoto, P., Blomme, A., Polese, C., Matheus, N., Cimino, J., Frère, A., Mouithys-Mickalad, A., Serteyn, D., Bettendorff, L., et al. (2017) · Oncogene · doi:10.1038/onc.2017.103 · Cited by 18
Metadata
- Authors
- Cheng, T., Grasse, L., Shah, J., & Chandra, J.
- Venue
- Drugs of Today
- Publisher
- Portico
- Published
- 2015
- Volume
- 51
- Issue
- 8
- Pages
- 491
- ISSN
- 0025-7656 (ISSN-L)
- 1699-4019
- OpenAlex
- W2216387124
- Cited by
- 32
- References
- 0
- FWCI
- 1.42
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Panobinostat, a pan-histone deacetylase inhibitor: Rationale for and application to treatment of multiple myeloma. https://app.cochat.ai/papers/10.1358/dot.2015.51.8.2362311
- The paper
- Cheng, T., Grasse, L., Shah, J., & Chandra, J. (2015). Panobinostat, a pan-histone deacetylase inhibitor: Rationale for and application to treatment of multiple myeloma. Drugs of Today. https://doi.org/10.1358/dot.2015.51.8.2362311
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.